stockrowCytokinetics, Incorporated
CYTK Healthcare Biotechnology
Cytokinetics, Incorporated’s revenue for fiscal 2025 (year ended December 2025) was $88.0 million, up 376.6% from fiscal 2024.
- Revenue
- +2,356.5%
- EPS
- +46.3%
- Free cash flow
- −6.73%
- Total debt
- −83.9%
Quarter to September 2026, against a year earlier
Follow CYTK
Alert me
Cytokinetics, Incorporated (CYTK) Return on assets
Cytokinetics, Incorporated's return on assets over the twelve months to 30 September 2026 was −47.7%, up 7.8 percentage points from fiscal 2025 (−55.6%). Over the past ten years it has ranged from −57.2% (fiscal 2023) to 11.5% (fiscal 2016); the current reading is higher than 18% of that period. That is in line with the Biotechnology industry median of −45.6% and below the Healthcare sector median of −29.3%.
Return on assets, annual
Embed this chart
Annual newest first
| Period | Return on assets | Change (points) |
|---|---|---|
| FY2025 | −55.6% | (2.58) |
| FY2024 | −53.0% | 4.26 |
| FY2023 | −57.2% | (15.32) |
| FY2022 | −41.9% | (10.59) |
| FY2021 | −31.3% | (0.41) |
| FY2020 | −30.9% | 17.67 |
| FY2019 | −48.6% | (6.57) |
| FY2018 | −42.0% | 12.96 |
| FY2017 | −55.0% | (66.50) |
| FY2016 | 11.5% | 41.75 |
Against its own ten years
Return on assets against peers
| Company | Return on assets |
|---|---|
| CORT Corcept Therapeutics Incorporated compare | 17.2% |
| KRYS Krystal Biotech, Inc. compare | 15.9% |
| PTGX Protagonist Therapeutics, Inc. compare | 10.3% |
| CAI Caris Life Sciences,�Inc. compare | 8.58% |
| MDGL Madrigal Pharmaceuticals, Inc. compare | −11.1% |
| ARWR Arrowhead Pharmaceuticals, Inc. compare | −18.3% |
| TWST Twist Bioscience Corporation compare | −20.8% |
| SYRE Spyre Therapeutics, Inc. compare | −30.9% |
| CYTK Cytokinetics, Incorporated | −47.7% |
| Biotechnology industry median | −45.6% |
| Healthcare sector median | −29.3% |
| Market median | 0.00% |
What Return on assets is
ROA tells an investor how much profit a company earns for shareholders from the assets it uses to run its business.
Annual: Net Income Allotted to Shareholders ÷ Average Assets; TTM: Net Income Allotted to Shareholders ÷ Average Assets (latest quarter)
More on CYTK
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement